LXS196 + LXS196 and HDM201
Phase 1Terminated 0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Uveal Melanoma
Conditions
Uveal Melanoma
Trial Timeline
Feb 1, 2016 → Jan 7, 2022
NCT ID
NCT02601378About LXS196 + LXS196 and HDM201
LXS196 + LXS196 and HDM201 is a phase 1 stage product being developed by Novartis for Uveal Melanoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT02601378. Target conditions include Uveal Melanoma.
What happened to similar drugs?
0 of 2 similar drugs in Uveal Melanoma were approved
Approved (0) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
6
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02601378 | Phase 1 | Terminated |
Competing Products
20 competing products in Uveal Melanoma